An aqueous formulation of γ-linolenic acid with anti-proliferative action on human pancreatic cancer cell lines

Anti-Cancer Drugs

Volumn 15, Issue 2, 2004, Pages 157-160

  Agombar, A ^a   Cooper, A J ^a   Johnson, C D ^a  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

In vitro study; Pancreatic cancer; Pancreatic cell lines; linolenic acid

Indexed keywords

GAMMA LINOLENIC ACID; LITHIUM GAMMA LINOLENIC ACID; MEGLUMINE; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

AQUEOUS SOLUTION; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL ASSAY; CELL PROLIFERATION; CONTROLLED STUDY; CYTOSTASIS; DOSE RESPONSE; DRUG ACTIVITY; DRUG FORMULATION; DRUG SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; TIME;

EID: 1542299084     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200402000-00009     Document Type: Article

References (15)

1. OPCS. Mortality Statistics - Serial Tables. Series DH1 25. London: HMSO; 1991.
2. Jiang WG, Bryce RP, Horrobin DF. Essential fatty acids: molecular and cellular basis of their anti-cancer action and clinical implications. Crit Rev Oncol Hematol 1998; 27:179-209.
3. Ravichandran D, Cooper A, Johnson CD. Growth inhibitory effect of lithium gammalinolenate on pancreatic cancer cell lines: the influence of albumin and iron. Eur J Cancer 1998; 34:188-192.
4. Ravichandran D, Cooper A, Johnson CD. Effect of lithium gamma-linolenate on the growth of experimental human pancreatic carcinoma. Br J Surg 1998; 85:1201-1205.
5. Hayashi Y, Fukushima S, Hirata T, Kishimoto S, Katsuki T, Nakano M. Anticancer activity of free gamma-linolenic acid on AH-109A rat hepatoma cells and the effect of serum albumin on anticancer activity of gamma-linolenic acid in vitro. J Pharmacobiodyn 1990; 13:705-711.
6. Hostmark AT, Lystad E. Growth inhibition of human hepatoma cells (HepG2) by polyunsaturated fatty acids. Protection by albumin and vitamin E. Acta Physiol Scand 1992; 144:83-88.
7. Johnson CD, Puntis M, Davidson N, Todd S, Bryce R. Randomized, dose-finding phase III study of lithium gamolenate in patients with advanced pancreatic adenocarcinoma. Br J Surg 88:662-668.
8. Solomon LZ, Jennings AM, Hayes MC, Bass PS, Birch BR, Cooper AJ. Is gamma-linolenic acid an effective intravesical agent for superficial bladder cancer? In vitro cytotoxicity and in vivo tolerance studies. Urol Res 1998; 26:11-15.
9. Solomon LZ, Jennings AM, Sharpe P, Cooper AJ, Birch BR. Intravesical chemotherapy with gamma linolenic acid becomes a realistic prospect in serum-free applications: in vitro cytotoxicity and systemic absorption studies [see Comments]. J Urol 1998; 160:2280-2283.
10. Das UN, Prasad VV, Reddy DR. Local application of gamma-linolenic acid in the treatment of human gliomas. Cancer Lett 1995; 94:147-155.
11. Naidu MR, Das UN, Kishan A. Intratumoral gamma-linoleic acid therapy of human gliomas. Prostaglandins Leuk Essent Fatty Acids 1992; 45:181-184.
12. Ravichandran D, Johnson CD. Anticancer effects of essential fatty acids. In: Johnson CD, Imrie CW (editors): Pancreatic Disease Towards the Year 2000. London: Springer; 1999, pp. 325-337.
13. Beger HG, Gansauge F, Buchler MW, Link KH. Intraarterial adjuvant chemotherapy after pancreaticoduodenectomy for pancreatic cancer; significant reduction in the occurrence of liver metastasis. World J Surg 1992; 23:946-949
14. Solomon LZ, Jennings AM, Foley SJ, Birch BR, Cooper AJ. Bladder cancer recurrence by implantation of exfoliated cells: is gamma-linolenic acid an effective tumoricidal agent? Br J Urol 1998; 82:122-126.
15. Ilc K, Fischel J-L, Formento P, Bryce R, Etienne M-C, Milano G. Cytotoxic effects of two gamma linoleic salts (lithium gammalinolenate or meglumine gammalinolenate) alone or associated with a nitrosourea: an experimental study on human glioblastoma cell lines. Anticancer Drugs 1999; 10:413-417.